Global Dengue Treatment Market Expected to Reach US$ 727 Million by 2027

Key Takeaways from the Study:

• The players including 
• Asia pacific accounts for a major share of the market, followed by Latin America. The market in Asia Pacific is projected to expand at significant CAGR during the forecast period.
•  In terms of value, the hospitals segment is anticipated to expand at a significant CAGR during the forecast period. Several governments bodies globally are willing to incorporate dengue vaccine in public immunization programs given assured quality, safety, and affordability of the vaccine in hospitals in endemic countries. This, in turn, creates awareness among the people about the dengue treatment, thus boosting segment growth.
• The parenteral segment is anticipated to expand at substantial CAGR during the forecast period. However, the oral segment is expected to account for a major share of the market during the forecast period.

Target Audience:

• Supply-side: Dengue vaccine and Drug manufacturers (Pharmaceutical Companies), raw material suppliers, primary respondents, and distributors.
• Demand Side: Hospitals, Clinics, Homecare, Pharmacies, Drug stores, Group Purchasing Organizations, Medical payers etc.
• Regulatory Side: Concerned government authorities, commercial research & development (R&D) institutions, and other regulatory bodies
• Associations and Industry Bodies: Centers for Disease Control and Prevention (CDC), National Institute of Allergy and Infectious Diseases (NIAID), Food and Drug Administration (FDA), World Health Organization (WHO), Medicines and Healthcare Products Regulatory Agency (MHRA), Therapeutic Goods Administration (TGA), Central Drug Standard Control Organization (CDSCO), Ministry of Health, Labor and Welfare (MHLW), International Federation of Pharmaceutical Manufacturers & Association (IFPMA), World Trade Organization (WTO), Indian Medical Research Council (ICMR).